Pain Management in Patients with Cervical Cancer

INTERVENTION: Intervention1: Drug Administration: Group II ‐ Patients receiving Dexmedetomidine 5 mcg (0.5ml) + hyperbaric levobupivacaine 10 mg (2.0 ml) Group III ‐ Patients receiving Dexmedetomidine 5 mcg (0.5ml) + 0.75% hyperbaric ropivacaine 15mg( 2.0ml) Frequency ‐ OD Route of Administration ‐ Intrathecal Control Intervention1: Standard drug administration: Group I‐ Patients receiving 0.5% hyperbaric bupivacaine 12.5mg (2.5 ml) Frequency ‐ OD Route of Administration ‐ Intrathecal CONDITION: Health Condition 1: C00‐D49‐ Neoplasms PRIMARY OUTCOME: Absolute duration of Spinal AnalgesiaTimepoint: 1hr, 4hr, 8hr, 12hr, and 24 hr SECONDARY OUTCOME: Quality of spinal analgesia ; Sedation scores ; Spinal block characteristics ; Pain Scores ; Dose requirement of rescue analgesics ; Incidence of nausea & vomiting ; Patient Satisfaction ScoresTimepoint: 1hr, 2hr, 4hr, 8hr, 24 hrs. INCLUSION CRITERIA: ASA Physical Status 1‐2 Patients with cervical carcinoma posted for intracavitary brachytherapy